Patents by Inventor Vita Golubovskaya
Vita Golubovskaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932703Abstract: The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.Type: GrantFiled: May 22, 2023Date of Patent: March 19, 2024Inventors: Vita Golubovskaya, Lijun Wu
-
Publication number: 20230383002Abstract: The present invention is directed to a humanized BCMA antibody or an antigen-binding fragment thereof, comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.Type: ApplicationFiled: May 31, 2023Publication date: November 30, 2023Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20230383009Abstract: The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.Type: ApplicationFiled: May 22, 2023Publication date: November 30, 2023Applicant: Caribou Biosciences, Inc.Inventors: Vita Golubovskaya, Lijun Wu
-
Publication number: 20230303708Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. A preferred co-stimulatory domain is CD28 or 41-BB. The humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.Type: ApplicationFiled: August 13, 2021Publication date: September 28, 2023Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20230295331Abstract: The present invention is directed to a monoclonal anti-human CS1 clone 7A8D5 antibody or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 4 and VL having the amino acid of SEQ ID NO: 5. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) CS1 scFv of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.Type: ApplicationFiled: August 2, 2021Publication date: September 21, 2023Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20230279140Abstract: The present invention is directed to humanized CD37-CAR comprising humanized CD37 scFv of the present invention. The present invention is also directed to a bispecific CD19-humanized CD37 CAR, comprising: (i) CD19 VL, (ii) Humanized CD37 ScFv, (iii) CD19 VH, (iv) a transmembrane domain, (v) at least one co-stimulatory domains, and (vi) an activating domain. The CARs of the present invention are useful in the field of adoptive immunity gene therapy for hematological cancers.Type: ApplicationFiled: July 23, 2021Publication date: September 7, 2023Inventors: Lijun Wu, Vita Golubovskaya
-
Patent number: 11725053Abstract: The present invention is directed to a chimeric antigen receptor fusion protein comprising: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against a tumor antigen, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the CAR further comprises a human transferrin fragment, which is an epitope for an antibody against human transferrin, at N-terminus or C-terminus to scFv, or between VH and VL. Preferred tumor antigens are CD19, CD22 and BCMA. The CD19-TF-CAR-T cells, CD22-TF-CAR-T cells, and BAMA-TF CAR-T cells secrete less cytokines, but they have the same efficacy against cancer target cells when comparing with same CAR without TF.Type: GrantFiled: June 18, 2020Date of Patent: August 15, 2023Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., LtdInventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20230227557Abstract: The present invention is directed to a monoclonal anti-human PD-L1 antibody, or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 3 and VL having the amino acid of SEQ ID NO: 5. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The inventors have shown that the PD-L1 CAR-T cells of the present invention are more effective than Avelumab PD-L1 CAR-T cells in killing several cancer cell lines. PD-L1 CAR-T can be used alone or in combination with other agent in an immunotherapy.Type: ApplicationFiled: June 16, 2021Publication date: July 20, 2023Inventors: Lijun Wu, Vita Golubovskaya
-
Patent number: 11692034Abstract: The present invention provides a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against CD47, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. In one embodiment, the scFv is derived from a humanized anti-CD47 antibody. The present invention also provides T cells modified to express the CAR of the present invention.Type: GrantFiled: July 24, 2019Date of Patent: July 4, 2023Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., LtdInventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20220356262Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.Type: ApplicationFiled: June 24, 2022Publication date: November 10, 2022Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20220348688Abstract: The present invention is directed to bispecific humanized PLAP (placental alkaline phosphatase)-CD3 epsilon chain (CD3e) antibodies. The present invention is further directed to a method for treating PLAP-positive cancer cells by administering the bispecific PLAP-CD3e antibody to the patients.Type: ApplicationFiled: June 29, 2022Publication date: November 3, 2022Inventors: Lijun Wu, Vita Golubovskaya
-
Patent number: 11472884Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.Type: GrantFiled: March 21, 2022Date of Patent: October 18, 2022Assignee: Caribou Biosciences, Inc.Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20220220217Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.Type: ApplicationFiled: March 21, 2022Publication date: July 14, 2022Applicant: Caribou Biosciences, Inc.Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20220220201Abstract: The present invention is directed to a monoclonal anti-human CS1 antibody or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 3 and VL having the amino acid of SEQ ID NO: 7. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.Type: ApplicationFiled: February 23, 2022Publication date: July 14, 2022Inventors: Lijun Wu, Vita Golubovskaya
-
Patent number: 11332513Abstract: The present invention is directed to a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv binds to a tumor antigen, (ii) a transmembrane domain, (iii) a co-stimulatory domain of GITR intracellular domain, and (iv) an activating domain. In one embodiment, the tumor antigen is human epidermal growth factor receptor (EGFR), human mesothelin, or human CD19. CARs having GITR intracellular domain as a co-stimulatory domain have certain advantages over other traditional CAR co-stimulatory domains.Type: GrantFiled: February 22, 2019Date of Patent: May 17, 2022Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., Ltd, The General Hospital CorporationInventors: Lijun Wu, Marcela V. Maus, Vita Golubovskaya
-
Patent number: 11299549Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.Type: GrantFiled: October 4, 2021Date of Patent: April 12, 2022Assignee: Caribou Biosciences, Inc.Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20220017633Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.Type: ApplicationFiled: October 4, 2021Publication date: January 20, 2022Applicant: CARIBOU BIOSCIENCES, INC.Inventors: LIJUN WU, VITA GOLUBOVSKAYA
-
Publication number: 20210395362Abstract: Provided is a humanized CD19 single-chain variable fragment (scFv) having a mutation of valine to glycine in CDR1, comprising VH having the amino acid sequence of SEQ ID NO: 6 and VL having the amino acid sequence of SEQ ID NO: 5. Also provided is a CD19 chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv), (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized CD19-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.Type: ApplicationFiled: May 28, 2021Publication date: December 23, 2021Applicant: ZHEJIANG RUIJIAMEI BIOTECH CO., LTD.Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20210395364Abstract: The present invention is directed to a humanized CD19 single-chain variable fragment (scFv), comprising the amino acid sequence of SEQ ID NO: 8. The present invention is also directed to a CD19 chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The humanized anti-CD19 scFv of the present invention exhibits selective and high-affinity binding to CD19. CD19-CAR T cells based on humanized scFv of the present invention are useful to treat patients with B-cell malignancies including leukemia and lymphomas.Type: ApplicationFiled: September 2, 2021Publication date: December 23, 2021Inventors: Lijun Wu, Vita Golubovskaya
-
Publication number: 20210347909Abstract: The present invention is directed to a humanized monoclonal anti-human EpCAM antibody, such as a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 2 and VL having the amino acid of SEQ ID NO: 4. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.Type: ApplicationFiled: July 21, 2021Publication date: November 11, 2021Inventors: Lijun Wu, Vita Golubovskaya